![SFX Search]()
Buy Article Permissions and Reprints
Publication History
Article published online:
12 November 2024
© 2024. Thieme. All rights reserved.
Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany
References
1
Hindricks G,
Potpara T,
Dagres N.
et al;
ESC Scientific Document Group.
2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): The Task Force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC. Eur Heart J 2021; 42 (05) 373-498
2
Kearon C,
Akl EA,
Ornelas J.
et al.
Antithrombotic therapy for VTE disease: CHEST Guideline and Expert Panel Report. Chest 2016; 149 (02) 315-352
3
Konstantinides SV,
Meyer G.
The 2019 ESC Guidelines on the Diagnosis and Management of Acute Pulmonary Embolism. Eur Heart J 2019; 40 (42) 3453-3455
4
Agnelli G,
Buller HR,
Cohen A.
et al;
AMPLIFY-EXT Investigators.
Apixaban for extended treatment of venous thromboembolism. N Engl J Med 2013; 368 (08) 699-708
5
Weitz JI,
Lensing AWA,
Prins MH.
et al;
EINSTEIN CHOICE Investigators.
Rivaroxaban or aspirin for extended treatment of venous thromboembolism. N Engl J Med 2017; 376 (13) 1211-1222
6
Camm AJ,
Cools F,
Virdone S.
et al;
GARFIELD-AF Investigators.
Mortality in patients with atrial fibrillation receiving nonrecommended doses of direct oral anticoagulants. J Am Coll Cardiol 2020; 76 (12) 1425-1436
7
Alcusky M,
Tjia J,
McManus DD,
Hume AL,
Fisher M,
Lapane KL.
Comparative safety and effectiveness of direct-acting oral anticoagulants versus warfarin: a National Cohort Study of Nursing Home Residents. J Gen Intern Med 2020; 35 (08) 2329-2337
8
Ruiz Ortiz M,
Muñiz J,
Raña Míguez P.
et al;
FANTASIIA Study Investigators.
Inappropriate doses of direct oral anticoagulants in real-world clinical practice: prevalence and associated factors. A subanalysis of the FANTASIIA Registry. Europace 2018; 20 (10) 1577-1583
9
Huisman MV,
Rothman KJ,
Paquette M.
et al;
GLORIA-AF Investigators.
The changing landscape for stroke prevention in AF: findings from the GLORIA-AF Registry Phase 2. J Am Coll Cardiol 2017; 69 (07) 777-785
10
Arbel R,
Sergienko R,
Hammerman A.
et al.
Effectiveness and safety of off-label dose-reduced direct oral anticoagulants in atrial fibrillation. Am J Med 2019; 132 (07) 847-855.e3
11
Poli D,
Antonucci E,
Ageno W.
et al;
Start AF Study Group.
Inappropriate underdosing of direct oral anticoagulants in atrial fibrillation patients: results from the START2-AF Registry. J Clin Med 2024; 13 (07) 2009
12
Chopard R,
Serzian G,
Humbert S.
et al.
Non-recommended dosing of direct oral anticoagulants in the treatment of acute pulmonary embolism is related to an increased rate of adverse events. J Thromb Thrombolysis 2018; 46 (03) 283-291
13
Steffel J,
Verhamme P,
Potpara TS.
et al;
ESC Scientific Document Group.
The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation. Eur Heart J 2018; 39 (16) 1330-1393
14
Eikelboom JW,
Weitz JI.
Direct oral anticoagulants in the very elderly. Thromb Haemost 2023; 123 (04) 377-379
15
Herron GC,
DeCamillo D,
Kong X.
et al.
Timing of off-label dosing of direct oral anticoagulants in three large health systems. Thromb Haemost 2024; (e-pub ahead of print) DOI:
10.1055/a-2365-8681.
16
Pereira MQ,
David C,
Almeida AG,
Brito D,
Pinto FJ,
Caldeira D.
Clinical effects of off-label reduced doses of direct oral anticoagulants: a systematic review and meta-analysis. Int J Cardiol 2022; 362: 76-82
17
Caso V,
de Groot JR,
Sanmartin Fernandez M.
et al.
Outcomes and drivers of inappropriate dosing of non-vitamin K antagonist oral anticoagulants (NOACs) in patients with atrial fibrillation: a systematic review and meta-analysis. Heart 2023; 109 (03) 178-185
18
Ruff CT,
Giugliano RP,
Braunwald E.
et al.
Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet 2014; 383 (9921) 955-962
19
Bo M,
Fumagalli S,
Degli Esposti L.
et al;
Italian Society of Geriatric Cardiology (SICGe).
Anticoagulation in atrial fibrillation. A large real-world update. Eur J Intern Med 2024; 121: 88-94
20
Palareti G,
Antonucci E,
Migliaccio L.
et al;
centers participating in the FCSA-START-Register (The ISCOAT 2016 study: Italian Study on Complications of Oral Anticoagulant Therapy-2016).
Vitamin K antagonist therapy: changes in the treated populations and in management results in Italian anticoagulation clinics compared with those recorded 20 years ago. Intern Emerg Med 2017; 12 (08) 1109-1119
21
Testa S,
Tripodi A,
Legnani C.
et al;
START-Laboratory Register.
Plasma levels of direct oral anticoagulants in real life patients with atrial fibrillation: results observed in four anticoagulation clinics. Thromb Res 2016; 137: 178-183
22
Parasrampuria DA,
Truitt KE.
Pharmacokinetics and pharmacodynamics of edoxaban, a non-vitamin K antagonist oral anticoagulant that inhibits clotting factor Xa. Clin Pharmacokinet 2016; 55 (06) 641-655
23
Miklič M,
Mavri A,
Vene N.
et al.
Intra- and inter- individual rivaroxaban concentrations and potential bleeding risk in patients with atrial fibrillation. Eur J Clin Pharmacol 2019; 75 (08) 1069-1075
24
Foulon-Pinto G,
Lafuente-Lafuente C,
Jourdi G.
et al.
Assessment of DOAC in GEriatrics (Adage Study): rivaroxaban/apixaban concentrations and thrombin generation profiles in NVAF very elderly patients. Thromb Haemost 2023; 123 (04) 402-414
25
Testa S,
Palareti G,
Legnani C.
et al.
Thrombotic events associated with low baseline direct oral anticoagulant levels in atrial fibrillation: the MAS study. Blood Adv 2024; 8 (08) 1846-1856
26
Palareti G,
Testa S,
Legnani C.
et al.
More early bleeds associated with high baseline direct oral anticoagulant levels in atrial fibrillation: the MAS study. Blood Adv 2024; 8 (18) 4913-4923
27
Okumura K,
Akao M,
Yoshida T.
et al;
ELDERCARE-AF Committees and Investigators.
Low-dose edoxaban in very elderly patients with atrial fibrillation. N Engl J Med 2020; 383 (18) 1735-1745
28
Yamashita T,
Igawa Y,
Fukuzawa M,
Hayashi T,
Hennig S,
Okumura K.
Pharmacokinetics of edoxaban 15 mg in very elderly patients with nonvalvular atrial fibrillation: a subanalysis of the ELDERCARE-AF study. Thromb Haemost 2024; 124 (09) 874-882
Publication History
留言 (0)